(Note: Current Rosetta Inpharmatics employees are shown in boldface type.)

Bangur CS¹, Switzer A¹, Fan L¹, Marton MJ², Meyer MR², Wang T¹, Correspondence: C S Bangur*

Abstract

Tumor Antigen Discovery, Corixa Corporation, 1124 Columbia Street, Seattle, Washington WA 98104, USA. bangur@corixa.com
To identify genes that are differentially over-expressed in Small Cell Lung Carcinoma (SCLC) we have used a combination of suppression subtractive hybridization and cDNA microarray to analyse the expression profiles of 2400 cDNAs clones. Genes that are over-expressed in SCLC were identified using 32 pairs of fluorescence-labeled cDNA samples representing various lung tumors and normal tissues. This comprehensive approach has resulted in the identification of 209 genes that are differentially over-expressed in SCLC. Quantitative real-time PCR was used to further validate the expression of 43 genes in SCLC tumors and various normal tissues. Discussed in this report are nine genes, which showed the most promising SCLC tumor to normal tissue differential expression profiles, including seven known and two novel genes. The large number of differentially expressed genes identified from this analysis and the characterization of these genes will provide valuable information in better understanding the biology of SCLC and help us in developing these gene products as potential targets for diagnostic as well as therapeutic usage.

¹Tumor Antigen Discovery
Corixa Corporation
1124 Columbia Street
Seattle, Washington WA 98104, USA.
bangur@corixa.com

² Rosetta Inpharmatics LLC
12040 115th Avenue NE
Kirkland, Washington 98034
USA

* E-mail: bangur@corixa.com